Ing. Ivana Ježíšková, Ph.D.
Researcher, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 4628 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 92
2024
-
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
American Journal of Hematology, year: 2024, DOI
-
MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia
CLINICAL EPIGENETICS, year: 2024, volume: 16, edition: 1, DOI
-
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
Blood advances, year: 2024, DOI
-
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Leukemia, year: 2024, DOI
2023
-
Acute myeloid leukemia suppression by palbociclib and ponatinib in patient-derived xenograft.
Year: 2023, type: Conference abstract
-
Analysis of factors influencing the decision to stop TKI treatment in CML patients in deep molecular response
Year: 2023, type: Conference abstract
-
Analýza genomu nemocných s akutní myeloidní leukémií (AML) metodou optického mapování (OGM).
Year: 2023, type: Conference abstract
-
Complex cytogenomic and molecular biological analysis of the tumor genome of patients with myeloid mylignancies with a focus on targeted analysis of the MECOM gene.
Year: 2023, type: Conference abstract
-
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech Center experience
Haematologica, year: 2023, volume: 108, edition: 10, DOI
-
Gemtuzumab ozogamicin s Midostaurinem v intenzivní léčbě CD33/FLT3+ AML – aktualizovaná data.
Year: 2023, type: Conference abstract